Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission [Yahoo! Finance]
Century Therapeutics, Inc. (IPSC)
Company Research
Source: Yahoo! Finance
increased its price target for Century Therapeutics to $4 from $2 with an Overweight rating, citing the company's plan to submit an IND for CNTY-813 this year and deliver initial data by 2027. Additionally, the firm highlighted Century's strong financial position, estimating a pro forma cash balance of approximately $267 million that is expected to fund operations through Q1 2029. Earlier on January 8, Clear Street analyst Bill Maughan reduced the price target for Century Therapeutics Inc. (NASDAQ:IPSC) to $6.60 from $8 while keeping a Buy rating. Maughan noted that a recent private placement extends the company's cash runway into Q1 2029, providing sufficient time to realize the full potential of its lead asset, CNTY-813, without requiring immediate additional capital. While the price target was lowered by Clear Street to account for dilution from the capital raise, the firm also emphasized that this was partially offset by an increased likelihood of pipeline success and higher p
Show less
Read more
Impact Snapshot
Event Time:
IPSC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSC alerts
High impacting Century Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IPSC
News
- Century Therapeutics (NASDAQ:IPSC) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IPSC&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Century Therapeutics (NASDAQ:IPSC) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IPSC&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
- Century Therapeutics (NASDAQ:IPSC) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes [Yahoo! Finance]Yahoo! Finance
IPSC
Earnings
- 11/13/25 - Miss
IPSC
Sec Filings
- 1/23/26 - Form 8-K
- 1/16/26 - Form SCHEDULE
- 1/16/26 - Form SCHEDULE
- IPSC's page on the SEC website